Circio calls EGM to approve NOK 50m rights issue

Circio Holding ASA announced an Extraordinary General Meeting (EGM) on January 12, 2026, to approve a proposed NOK 50 million rights issue. The offering, priced at NOK 1.00 per share, is significantly backed by pre-subscriptions totaling NOK 24.2 million from main shareholders and an additional NOK 20 million from an underwriter, securing 88.4% of the issue. Net proceeds are expected to fund operations for approximately 12 months, with an additional 1:1 warrant coverage potentially extending the cash runway into 2027.

The EGM agenda includes resolutions for share capital increases, warrant issuance, and the allocation of shares and warrants to pre-subscribers and the underwriter to settle commissions. A private placement is also proposed. The board seeks to renew authorization to increase share capital by 40% for future equity issues and to support share incentive programs.

The proposed rights issue will facilitate the advancement of Circio's pre-clinical circVec platform milestones and business development activities, including a recently announced feasibility study with a major global pharma company. The company’s legacy immuno-oncology program, TG01, targeting RAS-mutated cancers, will continue its development through cost-efficient external collaborations, with two ongoing clinical trials in Norway and the USA.